Maternal Glycated Albumin Tracks Fetal Overgrowth More Closely Than HbA1c
A prospective Danish cohort adds a new wrinkle to prenatal metabolic surveillance: glycated albumin rose in pregnancies that produced large-for-gestational-age infants, while HbA1c did not. The signal appeared early and persisted into mid-to-late pregnancy, suggesting that short-term maternal glycemic exposure may better mirror the fetal growth environment than the longer-term red-cell marker clinicians usually rely on.
The study followed 465 participants from a single-center observational cohort and measured albumin glycation at two gestational windows, 11 to 14 weeks and 23 to 31 weeks. Investigators used a rapid liquid chromatography-tandem mass spectrometry method to quantify site-specific albumin glycation at two positions, GA (KQT) and GA (KLV), along with their combined measure, GA-total. Stored serum samples provided a longitudinal view of maternal metabolism rather than a one-time snapshot, and that matters in pregnancy, where placental signaling, insulin resistance, and maternal substrate handling shift quickly across trimesters.
Site-Specific Albumin Glycation Distinguished Gestational Diabetes From Normal Pregnancy
The gestational diabetes pattern was not the same as the fetal-overgrowth pattern. In early pregnancy, women who later developed gestational diabetes mellitus had lower GA-total than non-GDM controls, and in the mid-to-late pregnancy window, only GA (KQT) remained lower in the GDM group. By contrast, HbA1c was higher in women with GDM at both timepoints, and higher HbA1c was associated with increased odds of GDM at each visit, with odds ratios of 2.20 and 2.30.
That split is clinically interesting. HbA1c integrates glycemia over a longer time horizon, but pregnancy changes erythrocyte turnover and can blunt its reliability as a pure metabolic readout. Glycated albumin, in contrast, reflects a shorter glycation window and may capture more immediate changes in maternal glucose handling. The site-specific behavior of GA also hints that not all albumin glycation carries the same biological signal; different lysine residues may respond differently to shifts in oxidative stress, protein turnover, or glucose flux.
Higher Glycated Albumin Marked the LGA Group at Both Timepoints
The most clinically consequential finding came from the fetal-growth analysis. Women in the LGA group had higher GA-total in early pregnancy and again in mid-to-late pregnancy. The association held in logistic models as well: GA-total was linked with increased odds of LGA at both timepoints, with odds ratios of 1.59 and 1.46.
The association was absent for HbA1c. Early and later in pregnancy, HbA1c did not show a significant relationship with LGA. For clinicians focused on preventing fetal overgrowth, that discrepancy suggests that a single HbA1c value may miss a metabolic pattern that GA can still detect. Fetal growth is exquisitely sensitive to maternal glucose exposure, especially in the setting of placental nutrient transport and fetal hyperinsulinemia. A marker that tracks near-term glycemic burden may therefore align more closely with the path toward accelerated somatic growth.
The biology is plausible even without overstatement. Maternal hyperglycemia increases transplacental glucose delivery, the fetus responds with increased insulin secretion, and insulin acts as a growth-promoting hormone in utero. Over time, that axis can translate into excessive fetal adiposity and larger birth size. The fact that GA carried the signal while HbA1c did not suggests that the relevant exposure may be narrower in time or more dynamically fluctuating than HbA1c can adequately capture.
Why the Direction of the GDM Signal Does Not Undo the LGA Signal
At first glance, lower GA in women with GDM seems counterintuitive beside the higher GA seen in LGA pregnancies. The likely explanation is that the two outcomes do not represent the same biological pathway. GDM diagnosis depends on formal glucose testing and reflects a threshold-based maternal metabolic phenotype, while LGA reflects cumulative fetal exposure to maternal fuels across pregnancy. A woman can meet diagnostic criteria for GDM yet still have lower measured GA at specific timepoints, especially if treatment, dietary changes, or physiologic variability altered glycemic exposure before sample collection.
This is where site-specific measurement may become useful rather than merely technical. The difference between GA (KQT) and GA (KLV) hints that albumin glycation is not a single uniform event. Different glycation sites may respond differently to maternal metabolism, and those differences could matter when the clinical question shifts from diagnosing GDM to anticipating fetal overgrowth.
A Rapid Mass Spectrometry Assay Strengthens the Case for Translation
The assay itself is part of the story. A rapid liquid chromatography-tandem mass spectrometry method allowed quantification of site-specific albumin glycation in stored samples, making the analysis feasible in a prospective cohort. For obstetric and endocrine teams, that kind of analytic precision matters because it raises the possibility of a future biomarker panel that complements routine prenatal testing rather than replacing it.
The study also had the strengths expected of a longitudinal design: samples were drawn at two gestational timepoints, and outcomes were linked to prospectively collected cohort data. Ethical approval was obtained from the local Committee on Health Research Ethics of the Capital Region of Denmark, and participants gave written informed consent. The work was not peer reviewed, so the findings remain provisional, but the internal consistency of the LGA association across both gestational windows gives the result clinical weight.
What the Data Support, and What They Do Not Yet Prove
The results support a narrow but important proposition: glycated albumin may add risk information for fetal overgrowth beyond HbA1c. They do not establish that GA should enter routine prenatal care, and they do not show that acting on GA would improve outcomes. The cohort was single-center, and the abstract does not provide enough detail to judge calibration, predictive discrimination, or how GA might perform alongside glucose challenge testing, maternal body mass index, or treatment status.
Still, the central message is hard to ignore. A biomarker that mirrors recent maternal glycemic exposure may be better aligned with the fetal growth phenotype than a longer-term hemoglobin measure. In a field where early identification of excess fetal growth can shape counseling, surveillance, and delivery planning, that difference could become clinically relevant if future studies confirm it in broader populations and show that GA adds value beyond standard obstetric screening.